A longitudinal study of plasma levels of soluble fms‐like tyrosine kinase 1 (sFlt1), placental growth factor (PlGF), sFlt1: PlGF ratio and vascular endothelial growth factor (VEGF‐A) in normal pregnancy
Authors:
Open Access
- 13 May 2011
- journal article
- research article
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 90 (11) , 1244-1251
Abstract
Objective. To describe plasma levels of angiogenic (PlGF, VEGF‐A) and anti‐angiogenic (sFlt1) factors as well as the sFlt1:PlGF ratio throughout normal pregnancy and postpartum. Design. Longitudinal prospective study. Setting. One outpatient antenatal clinic in Uppsala, Sweden. Population. Thirty‐seven healthy women with normal pregnancies and normal neonatal outcome were included. Methods. Blood samples were collected from each woman at least six times. Plasma levels of sFlt1, PlGF and VEGF‐A were measured using commercially available ELISA kits. Main outcome measures. Median plasma levels, the 25th to the 75th percentile and the average change per gestational week of sFlt1, PlGF and the sFlt1:PlGF ratio. Results. sFlt1 levels were relatively constant until weeks 29–30, when they increased, reaching a peak at week 40. An increase of 643pg/ml per week was observed from weeks 30 to 40. Postpartum levels were low. PlGF increased by 16pg/ml per week from early pregnancy until weeks 29–30 and thereafter decreased by 14pg/ml per week until week 40. The sFlt1:PlGF ratio decreased from weeks 9–12, was constantly low from weeks 19–20 to 37–38 and then increased to weeks 39–40. VEGF‐A was detectable in only 8% of the samples during pregnancy and in 64% postpartum. Conclusion. This longitudinal study demonstrates how sFlt1, PlGF and the sFlt1:PlGF ratio fluctuate throughout normal pregnancy and postpartum and may serve as a reference against which these factors can be studied in complicated pregnancies. VEGF‐A levels were more often detectable postpartum.Keywords
This publication has 25 references indexed in Scilit:
- A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonateThe Journal of Maternal-Fetal & Neonatal Medicine, 2008
- Evidence supporting that the excess of the sVEGFR-1 concentration in maternal plasma in preeclampsia has a uterine originThe Journal of Maternal-Fetal & Neonatal Medicine, 2005
- Angiogenic imbalance in the pathophysiology of preeclampsia: Newer insightsSeminars in Nephrology, 2004
- Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsiaJournal of Clinical Investigation, 2003
- The Role of Vascular Endothelial Growth Factor in AngiogenesisActa Haematologica, 2001
- Placental angiogenesis: the role of the VEGF family of proteinsAngiogenesis, 1998
- Vascular endothelial growth factor, placenta growth factor and their receptors in isolated human trophoblastPlacenta, 1997
- Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawalProceedings of the National Academy of Sciences, 1997
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisCell, 1996
- Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor.Proceedings of the National Academy of Sciences, 1993